Gene · 211
Papers1,411
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,411
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrated Analysis of Single-Cell and Bulk RNA Data Reveals Complexity and Significance of the Melanoma Interactome. | Cancers (Basel) | 2025 | 39796775 | PubTator, text mining | PubMed |
| Rational Design Engineering of 5-Aminolevulinate Synthase with Activity and Stability Enhancement. | J Agric Food Chem | 2025 | 39772634 | PubTator, text mining | PubMed |
| 5-Aminolevulinic Acid (5-ALA) Plays an Important Role in the Function of Innate Immune Cells. | Inflammation | 2025 | 39702622 | PubTator, text mining | PubMed |
| Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti-Tuberculosis Drug-Induced Liver Injury. | J Clin Pharmacol | 2025 | 39297668 | PubTator, text mining | PubMed |
| Case-based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management. | Liver Int | 2025 | 38618923 | PubTator, text mining | PubMed |
| Trends in drug development for rare and intractable diseases based on the KEGG NETWORK. | NAR Mol Med | 2024 | 41256806 | PubTator, text mining | PubMed |
| Givosiran: a targeted treatment for acute intermittent porphyria. | Hematology Am Soc Hematol Educ Program | 2024 | 39644007 | PubTator, text mining | PubMed |
| German Real-World Experience of Patients with Diverse Features of Acute Intermittent Porphyria Treated with Givosiran. | J Clin Med | 2024 | 39597922 | PubTator, text mining | PubMed |
| Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study. | Orphanet J Rare Dis | 2024 | 39363243 | PubTator, text mining | PubMed |
| Heme deficiency in skeletal muscle exacerbates sarcopenia and impairs autophagy by reducing AMPK signaling. | Sci Rep | 2024 | 39333763 | PubTator, text mining | PubMed |
| Pyridoxine: beyond a cofactor of ALAS. | Blood | 2024 | 39325482 | PubTator, text mining | PubMed |
| Association of DNA methylation, polymorphism and mRNA level of ALAS1 with antituberculosis drug-induced liver injury. | Pharmacogenomics | 2024 | 39263813 | PubTator, text mining | PubMed |
| AlphaFold2 in biomedical research: facilitating the development of diagnostic strategies for disease. | Front Mol Biosci | 2024 | 39139810 | PubTator, text mining | PubMed |
| Heterologous Expression and Purification of Eukaryotic ALA Synthase from E. coli. | Methods Mol Biol | 2024 | 39008257 | PubTator, text mining | PubMed |
| An adaptor for feedback regulation of heme biosynthesis by the mitochondrial protease CLPXP. | bioRxiv | 2024 | 39005287 | PubTator, text mining | PubMed |
| RPLP0/TBP are the most stable reference genes for human dental pulp stem cells under osteogenic differentiation. | World J Stem Cells | 2024 | 38948092 | PubTator, text mining | PubMed |
| Elucidating the Role of Human ALAS2 C-terminal Mutations Resulting in Loss of Function and Disease. | Biochemistry | 2024 | 38888931 | PubTator, text mining | PubMed |
| Update on heme biosynthesis, tissue-specific regulation, heme transport, relation to iron metabolism and cellular energy. | Liver Int | 2024 | 38888238 | PubTator, text mining | PubMed |
| The radical impact of oxygen on prokaryotic evolution-enzyme inhibition first, uninhibited essential biosyntheses second, aerobic respiration third. | FEBS Lett | 2024 | 38750628 | PubTator, text mining | PubMed |
| Preventing hyperhomocysteinemia using vitamin B6 supplementation in Givosiran-treated acute intermittent porphyria: Highlights from a case report and brief literature review. | Mol Genet Metab Rep | 2024 | 38601120 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/211/papers?page=3